Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in non-small cell lung cancer (NSCLC) patients with drug-sensitive EGFR mutations. However, in some TKI responders, the benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hsian-Yu, Hsu, Min-Kung, Wang, Kai-Hsuan, Tseng, Ching-Ping, Chen, Feng-Chi, Hsu, John T-A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881734/
https://www.ncbi.nlm.nih.gov/pubmed/27284246
http://dx.doi.org/10.2147/OTT.S96341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881734/
https://www.ncbi.nlm.nih.gov/pubmed/27284246
http://dx.doi.org/10.2147/OTT.S96341

Ejemplares similares